Clicky

Cytokinetics, Incorporated(CYTK)

Description: Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is in Phase II clinical development for the potential treatment of heart failure. The company also holds an exclusive license worldwide to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing Tirasemtiv and CK-2127107, which are skeletal muscle activators, as potential treatments for diseases and medical conditions associated with aging, muscle wasting, or neuromuscular dysfunction. Tirasemtiv is in Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment, in which treatment with tirasemtiv produced potentially clinically relevant pharmacodynamic effects in Phase II trials. The company has a strategic alliance with Amgen Inc. to discover, develop, and commercialize small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.


Keywords: Biopharmaceutical Disease Neuroscience Product Design Clinical Development Heart Failure Dysfunction Amyotrophic Lateral Sclerosis Nervous System Serious Diseases Orphan Drug Cytokine Drug Design Molecule Therapeutics Treatment Of Heart Failure Medicinal Product Treatment Of Serious Diseases

Home Page: www.cytokinetics.com

CYTK Technical Analysis

350 Oyster Point Boulevard
South San Francisco, CA 94080
United States
Phone: 650 624 3000


Officers

Name Title
Mr. Robert I. Blum CEO, Pres & Director
Mr. Ching W. Jaw Sr. VP & CFO
Dr. Fady Ibraham Malik FACC, M.D., Ph.D. Exec. VP of R&D
Mr. Andrew M. Callos Exec. VP & Chief Commercial Officer
Dr. James A. Spudich Ph.D. Co-Founder & Member of Scientific Advisory Board
Mr. Jeff Lotz VP of Sales & Operations
Mr. Robert C. Wong VP & Chief Accounting Officer
Ms. Joanna Siegall Associate Director of Corp. Communications & Investor Relations
Ms. Kari K. Loeser J.D. VP & Chief Compliance Officer
Mr. Scott R. Jordan Sr. VP of Global Marketing & Commercial Strategy

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 31.8985
Price-to-Sales TTM: 27.5151
IPO Date: 2004-04-29
Fiscal Year End: December
Full Time Employees: 253
Back to stocks